NAD

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Retrieved on: 
Monday, October 2, 2023
Research, General Health, Pharmaceutical, Consumer, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Seniors, Alternative Medicine, Vitamins, Supplements, Health, Exercise, DNA, Human, Nicotinamide adenine dinucleotide, Diabetes, Metabolism, NR, Nicotinamide riboside, Cardiovascular disease, ATP, Clinical trial, Ageing, NAD, ChromaDex, National Heart, Lung, and Blood Institute, Inflammation, Cell, Lung, Lupus, Bangladesh Technical Education Board, Trial of the century, Psoriasis, Amna Elhassan, NHLBI, Patient, Polyphosphate, Sleep deprivation, Conditional sentence, Smoking, Adenosine triphosphate, MRC Mitochondrial Biology Unit, NIH, Cell Reports, DNA repair, Pharmaceutical industry, Dietary supplement

The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.

Key Points: 
  • The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.
  • This is Dr. Sack’s fourth published study on NR, and the seventh clinical study overall, that demonstrates NR’s effectiveness in reducing inflammation, an important indicator of how the body is aging,” remarked Rob Fried, CEO of ChromaDex.
  • This is the third published human clinical study demonstrating that NR supplementation has a protective effect in healthy individuals and lays the foundation for future clinical research ( Elhassan et al.
  • Research suggests a depletion of NAD+ is associated with impaired inflammatory responses and innate immune dysfunction, indicating NAD+ levels may have a critical impact on the function of immune cells.

Introducing MeltMed: First to Market Fast-Dissolving Nutraceutical Wafers to Address Anti-Aging Skin Care, Energy, and Immune Health

Retrieved on: 
Wednesday, September 27, 2023
Business development, Availability, RRP, Antioxidant, Ageing, Therapeutic Goods Administration, NAD, Nutrient, Immunity, Medicine, Absorption, Pharmacy, USD, Cornerstone, Chemistry, CGMP, Regeneration, TGA, Tongue, Skin, Dietary supplement, Glutathione, Radiance

NEW YORK, Sept. 27, 2023 /PRNewswire/ -- MeltMed, an innovative supplement brand revolutionizing the way consumers experience nutraceuticals, is unveiling a new suite of fast-dissolving wafer products in the United States. The new supplements feature nicotinamide adenine dinucleotide (NAD+) and glutathione, which support healthy aging and skin health, respectively, among other functions.

Key Points: 
  • The new supplements feature nicotinamide adenine dinucleotide (NAD+) and glutathione, which support healthy aging and skin health, respectively, among other functions.
  • Radiance with Glutathione - Glutathione is the key ingredient, supporting visibly smoother, more radiant, and more supple skin.
  • MeltMed is a wholly owned subsidiary of iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company listed on the Singapore Exchange Securities Trading Limited.
  • In celebration of their upcoming launch, MeltMed will be offering a storewide discount of 30% off RRP on their website.

CCM Biosciences Announces Launch of Protein Upregulation Business Unit

Retrieved on: 
Wednesday, September 20, 2023
Medicinal chemistry, National academy, SIRT1, University, Chemical physics, Mitochondrion, Bioorganic & Medicinal Chemistry, Enzyme, NAD, Mutation, RNA, Infertility, Cystic fibrosis, SIRT3, Alzheimer's disease, University of Palermo, Parkinson's disease, Protein, CCM, Publication, Journal, Patient, PLOS, Biophysics, Fertility, The Journal of Chemical Physics, Regulation, Cystic Fibrosis Foundation, Physics, Longevity, Notifiable disease, IND, Gene, Sirtuin, Library, Messenger, Dietary supplement, Pharmaceutical industry, Vaccine

MOUNT LAUREL, N.J., Sept. 20, 2023 /PRNewswire/ -- CCM Biosciences, a pharmaceutical discovery and development company that recently confirmed its launch from stealth, today announced its latest business unit — CCM Protein Upregulation — dedicated to advancing first-in-class drug leads for age-related conditions such as Alzheimer's, Parkinson's, and infertility as well as for genetically inherited diseases such as cystic fibrosis, using highly differentiated technology platforms for improving the enzymatic activity or expression level of critical proteins implicated in the pathogenesis of such disorders. 

Key Points: 
  • New business unit is focused on "undruggable" targets for age-related indications and genetically inherited diseases.
  • Enhancement of the activity or expression level of proteins is important for the treatment of many age-related and genetically inherited conditions.
  • Such compounds have the potential to rejuvenate the activity of SIRT3 to levels observed in youth," said Dr. Raj Chakrabarti, CEO of CCM Biosciences.
  • CCM Protein Upregulation's drug leads represent a first-in-class opportunity to treat multiple diseases caused by nonsense mutations.

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Retrieved on: 
Thursday, August 24, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, ENT, Human, Nicotinamide adenine dinucleotide, Cell membrane, Diet, Metabolism, Ageing, NMN, NAD, Multimedia, CD73, ChromaDex, Ivan Kropotov, Edward Conze, Assistant, Protein, Molecular genetics, G.H. Raisoni Department of Microbiology and Biotechnology, Canadian International Council, Weill Cornell Medicine, Mouse, Nicotinamide mononucleotide, International Journal of Molecular Sciences, UCLA, Isotope, Environmental Molecular Sciences Laboratory, Pharmaceutical industry, Phosphorus, Immunology, Pharmacology

The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.

Key Points: 
  • The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.
  • These results build on a growing body of research demonstrating that NMN cannot cross the cell membrane directly and must first be converted to NR.
  • Because NR can cross the cell membrane directly, this data, along with other science, indicates that NR is a more efficient NAD+ precursor than NMN.
  • NR and NMN are chemically identical except for a phosphate group present within the structure of NMN.

Hydreight Announces Nationwide Expansion of Doctor Network to Meet Demand Across All 50 US States

Retrieved on: 
Thursday, August 24, 2023
Nicotinamide adenine dinucleotide, Pharmacy, Agonal respiration, FSE, Sleep apnea, LAS, Organization, NURS, NAD, Patient, Physician, PCOS, Nursing, Addiction, Ecosystem, Health, Health insurance, Pharmaceutical industry, Semaglutide

The Company has successfully increased its network to over 100 physicians spanning across all 50 US states by contracting with an independent network of affiliated medical practices to facilitate the delivery of services to patients.

Key Points: 
  • The Company has successfully increased its network to over 100 physicians spanning across all 50 US states by contracting with an independent network of affiliated medical practices to facilitate the delivery of services to patients.
  • “The expansion of our doctor network complements our established network of nurses, business partners and pharmacies.
  • Additionally, through the Company’s white-label strategy, the doctor network extends its reach to benefit other franchises and organizations seeking these services.
  • The Hydreight platform connects patients and providers, seamlessly integrates compliance and medical oversight with the convenience and personalized care and one-on-one interactions.

Cutting-Edge IV Therapy is Officially Touching Down in Phoenix!

Retrieved on: 
Sunday, August 20, 2023
IV, Cancer, NAD, Jim Pederson (businessman and politician), Patient, Conditional sentence, Longevity, Mental health, Fireworks, Medical device, PHOENIX, Phoenix

PHOENIX, Aug. 20, 2023 /PRNewswire-PRWeb/ -- August 2023: The DRIPBaR is excited to announce the opening of its newest location in Phoenix, AZ on August 21. This marks the newest location for the franchise, with approximately 600+ additional locations in the pipeline.

Key Points: 
  • The DRIPBaR is a nationwide franchise focused on helping people obtain their best physical and mental health through IV vitamin therapy.
  • To celebrate their grand opening, The DRIPBaR Phoenix Biltmore is offering 50% off any IV drip and a FREE B12 Shot when you book before opening day.
  • The DRIPBaR Phoenix will offer all of the popular DRIPBaR IV vitamin therapy services and more!
  • Customers can choose from a variety of IV Lifestyle and IV Health Support Drips, designed to help them look and feel their best.

Elevate Your Beauty and Wellness Regime with LAC Taut and LAC NMN

Retrieved on: 
Tuesday, July 11, 2023
Elasticity, DNA, Radical, Placenta, Glycation, Skin, NMN, NAD, AG, Envy, Cofactor, Beauty, Metabolism, RDS, Longevity, Nicotinamide mononucleotide, Health, LAC, Antioxidant, DNA repair, Sulfur

LAC, Leader in Antioxidative Control(TM), has prepared a trove of skincare treasures, offering you lifelong beauty and wellness.

Key Points: 
  • LAC, Leader in Antioxidative Control(TM), has prepared a trove of skincare treasures, offering you lifelong beauty and wellness.
  • LAC's signature range of wellness supplement products: LAC Taut(R) Rejuvenate+ Premium Collagen 13,000mg Plus Placenta & AG Complex and LAC NMN, nourishes you right from the core of the body.
  • Its high-quality, effective, scientifically-backed formulations rejuvenate the most tired and lifeless skin, restoring the glow that we have all eagerly yearned for.
  • Be at the centre of all envy with LAC Taut(R) Rejuvenate+.

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Tru, Glaucoma, Heart, Abstract, ARVO, Marketing, NR, Replay, NAD, GAAP, ChromaDex, Brain, History, Trial of the century, Net, EBITDA, Acquisition, Patient, Investment, Annual report, Investigative Ophthalmology & Visual Science, Webcast, Growth, Association for Research in Vision and Ophthalmology, Infant, Security (finance), Adjustment, Conference, WalletHub, Video game, Pharmaceutical industry, Communications satellite, Ophthalmology

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.
  • Net loss was $2.2 million or $(0.03) per share, an improvement of $4.2 million, or $0.06 per share, from the prior year quarter.
  • Adjusted EBITDA, a non-GAAP measure, was a positive $0.2 million, a $4.9 million improvement from the prior year quarter.
  • “This was another excellent quarter, delivering 21% year-over-year revenue growth, positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the second consecutive quarter,” said ChromaDex Chief Executive Officer, Rob Fried.

Nuveen Municipal Closed-End Funds Announce Merger Proposals

Retrieved on: 
Wednesday, August 9, 2023
Other Professional Services, Asset Management, Professional Services, Finance, NVG, Nuveen, NAD, Montanile v. Board of Trustees of Nat. Elevator Industry Health Benefit Plan, NEA, NMT, Trustee, NYSE, Indian Sugar Mills Association, NQP, Security (finance), Casino, Pension fund

The Boards of Trustees of six Nuveen municipal closed-end funds approved three merger proposals.

Key Points: 
  • The Boards of Trustees of six Nuveen municipal closed-end funds approved three merger proposals.
  • The proposed mergers for the funds are subject to certain conditions, including necessary approval by the funds’ shareholders.
  • Nuveen Massachusetts Quality Municipal Income Fund (NYSE: NMT)
    Nuveen AMT-Free Quality Municipal Income Fund (NYSE: NEA)
    Nuveen Pennsylvania Quality Municipal Income Fund (NYSE: NQP)
    Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG)
    Nuveen New Jersey Quality Municipal Income Fund (NYSE: NXJ)
    Nuveen Quality Municipal Income Fund (NYSE: NAD)
    Detailed information on the proposed mergers will be contained in proxy materials expected to be filed in the coming weeks.
  • Nuveen is a leading sponsor of closed-end funds (CEFs) with $53 billion of assets under management across 51 CEFs as of 30 Jun 2023.

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

Retrieved on: 
Tuesday, August 8, 2023
Online Retail, Retail, Health, General Health, Research, Science, Nobel Prize, Vitacost, Life, NR, House (brand), Ageing, NAD, ChromaDex, GNC, SVP, Family, Abrasive

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.
  • iHerb is on a mission to make health and wellness accessible to all offering the best brands in the industry and has established a strong international presence, with nearly 90% of sales generated outside of the United States.
  • iHerb has a global audience larger than Vitacost, VitaminShoppe, and GNC combined, proudly totaling 10 million active customers across more than 180 countries.
  • “NAD+ is essential for life, yet our levels decrease with age and when we are under physiological stress,” commented Rob Fried, CEO of ChromaDex.